StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.41+0.05 (+13.12%)

Close on Nov 18, 2026Market cap $99.30MP/E –Yield –

Outlook Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Outlook Therapeutics's price to book ratio was 42.3× on Jul 31, 2023, against 5.2× a year earlier. Over the last 3 years it ranged from 4.7× to 58.5×, with a median of 27.1×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jul 31, 202342.3×+14.2
2022Dec 30, 202228.1×−24.0
2021Dec 31, 202152.1×−6.4
2020Dec 31, 202058.5×–

More Outlook Therapeutics figures

See a number that looks wrong?